Industry News

MSN has announced the successful launch of its Teduglutide Injection across several key European markets, marking a significant milestone in the company’s development of complex peptide medicines.

The launch is based on the dossier developed by MSN following the first generic approval for Teduglutide in Europe. According to the company, the achievement also makes MSN the first company to secure approval for a generic Teduglutide dossier in a G7 nation.

Amgen Inc. has disclosed a material cybersecurity incident after identifying unauthorized activity involving data stored in cloud environments hosted by third-party service providers. The company revealed the incident in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (SEC).

According to the filing, Amgen detected the unauthorized activity in July 2026 and immediately activated its cybersecurity incident response plan. The company implemented containment measures and engaged independent cybersecurity forensic experts to investigate the breach.

Sandoz has announced significant progress in resolving long-standing U.S. litigation related to the generic medicines market, entering into settlement agreements covering the majority of its remaining legacy antitrust cases in the United States. The company stated that the agreements are intended to resolve historical legal disputes while allowing it to remain focused on its core business of expanding access to affordable medicines.

Dr. Reddy’s Laboratories has received approval from the U.S. Food and Drug Administration (FDA) for its rituximab biosimilar, a biosimilar version of Rituxan® (rituximab), marking another significant milestone in the company's expanding global biosimilars business.

The approval enhances Dr. Reddy’s biologics portfolio and reinforces its presence in the highly regulated U.S. pharmaceutical market. The biosimilar was developed, manufactured, and submitted for approval entirely by Dr. Reddy’s Laboratories.

AstraZeneca Plc has held discussions with U.S.-based Bristol Myers Squibb (BMS) over a potential merger that could create one of the world's largest pharmaceutical companies with a combined market value of nearly $400 billion, according to an exclusive report by the Financial Times, which cited people familiar with the matter.

Sun Pharmaceutical Industries Ltd., India's largest pharmaceutical company, has announced a strong start to FY2026-27, reporting double-digit revenue growth in the first quarter ended June 30, 2026. Robust performance in the domestic formulations business and continued momentum in its innovative medicines portfolio helped the company deliver higher sales and profitability despite softer demand in the U.S. generics market.

Sun Pharma announced that it has received approval from the Brazilian Health Regulatory Agency, ANVISA to manufacture and market semaglutide injection in Brazil for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

Sun Pharma plans to launch the product in the next few days in partnership with Hypera Pharma, a leading pharmaceutical company in Brazil. It will be available as a pre-filled, multi-dose injectable pen in two strengths (2 mg/1.5 mL and 4 mg/3 mL) allowing flexible, once-weekly dosing.

Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch1 of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark’s Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225].

According to IQVIA® sales data for the 12-month period ending May 2026, the BRIDION® Injection, 100 mg/mL market3 achieved annual sales of approximately 1.6 billion USD.